Siltuximab for First-Line Treatment of Cytokine Release Syndrome: A Response to the National Shortage of Tocilizumab

托珠单抗 细胞因子释放综合征 医学 内科学 经济短缺 第二线 白细胞介素6 免疫学 药理学 第一行 细胞因子 2019年冠状病毒病(COVID-19) 传染病(医学专业) 疾病 政府(语言学) 哲学 语言学
作者
Seema Patel,Danielle Cenin,Donna Corrigan,Betty K. Hamilton,Matt Kalaycio,Ronald Sobecks,Faiz Anwer,Jack Khouri,Robert M. Dean,Allison Winter,Deepa Jagadeesh,Brad Pohlman,Brian T. Hill,Craig S. Sauter,Paolo Caimi
出处
期刊:Blood [Elsevier BV]
卷期号:140 (Supplement 1): 5073-5074 被引量:10
标识
DOI:10.1182/blood-2022-169809
摘要

Introduction Chimeric antigen receptor T (CAR T) cells targeting CD19 and BCMA are active in the treatment of B cell lymphoid malignancies. CAR T cell therapy can be complicated by cytokine release syndrome (CRS), a syndrome characterized by systemic inflammatory response, in which interleukin (IL) -6 plays a central role. Tocilizumab is a monoclonal antibody targeting the IL-6 receptor and is recommended for treatment of CRS. A national shortage of tocilizumab occurred in 2021. In order to conserve supply and continue providing CAR T cell therapy, our center replaced tocilizumab with siltuximab in our CRS management algorithm. Siltuximab is a monoclonal antibody that binds to IL-6 itself. We report the outcomes of patients treated with this "siltuximab-first” (SF) approach in comparison with patients treated with a "tocilizumab-first” (TF) based approach. Methods We conducted a retrospective review of patients treated with CAR T cells for lymphoma and multiple myeloma. Baseline characteristics and outcomes were collected from the transplant and cellular therapy database and medical records. CRS was graded according to the Lee scale and immune effector cell-associated neurotoxicity syndrome (ICANS) was graded according to the CAR T cell toxicity management grading system. At our center, anti-IL-6 therapy is utilized for grade 2 or greater CRS, or persistent grade 1 per provider discretion. The length of stay for CAR T hospitalization was measured from the day of CAR T cell infusion. Comparisons between groups were done using Fisher's exact test for nominal variables and Kruskal-Wallis rank sum test for continuous variables. All analyses were done using R and its packages. Results We identified 135 patients treated with CAR T cell therapy. Baseline characteristics are listed in Table 1. The majority of patients received treatment for relapsed or refractory B cell non Hodgkin lymphoma (NHL). CRS was observed in 95 (70.4%) patients, 44 (32.5%) had grade ≥ 2 CRS. Patients treated with the SF and TF protocols had comparable rates of CRS (SF = 67.5% vs. TF = 71.6%, p = 0.68) as well as grade ≥ 2 CRS (SF = 27.5% vs. TF = 33.3%, p = 0.54). Fifty one (37.8%) patients developed neurotoxicity, 23 (17%) grade ≥ 2, without differences between groups. Anti-IL-6 therapy was prescribed to 60 (44.4%) patients, without significant differences between groups (SF = 47.5% vs. TF = 43.2%, p = 0.71). The median number of doses of cytokine blocking agents was 1 (IQR 1 - 2), without a significant difference between groups. A larger proportion of patients with MM were treated using the SF CRS protocol (37.5% vs. 10.5%, p <0.001). Fourteen out of 19 patients (73.7%) treated with SF required only one dose of anti-IL-6 directed therapy, compared with 21/40 (51.2%) patients treated with TF. However, this difference did not reach statistical significance. Seven doses of tocilizumab were used in 5 patients during the period of SF protocol use, primarily due to persistent CRS after an initial dose of siltuximab or physician discretion. Thirty three patients (24.4%) received corticosteroids (inclusive of treatment of neurotoxicity), without differences in the proportions between groups (SF = 25.0% vs. TF= 24.2%, p = 1). Transfer to an intensive care unit (ICU) setting occurred in 14 (10.4%) cases, without significant differences between groups. Median length of stay (LOS) for the entire cohort was 10 days (IQR 7-14). Patients experiencing CRS had longer median LOS (12 vs. 7 days, p <0.001). The median LOS of patients with CRS requiring IL-6 blockade was 10.5 and 14 days for SF and TF, respectively (p = 0.09). Conclusions IL-6 blockade is an effective therapy for CRS. Adoption of a "siltuximab first” protocol in response to the national shortage of tocilizumab showed that the use of this agent is safe and feasible. We did not observe increased use of subsequent doses of anti-IL-6 therapy or steroids, and hospital resource utilization measures such as ICU transfer and LOS were comparable with tocilizumab - based protocols. The larger proportion of MM patients receiving the SF protocol can be attributed to timing of CAR T product approval and tocilizumab shortage. Differences in LOS are likely a result of population and time period differences. While prospective studies in larger numbers of patients may be needed, these results suggest siltuximab is a valid alternative for CRS management in CAR T cell patients. Figure 1View largeDownload PPTFigure 1View largeDownload PPT Close modal
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
神勇依波发布了新的文献求助10
刚刚
刚刚
小琪猪完成签到,获得积分10
1秒前
SciGPT的应助被cheers采纳,获得10
1秒前
正直三颜完成签到,获得积分10
1秒前
无花果的应助被饱满的皮皮虾采纳,获得10
2秒前
3秒前
甜美三娘完成签到,获得积分10
3秒前
华琪完成签到,获得积分20
4秒前
4秒前
5秒前
tony完成签到,获得积分10
5秒前
子焱发布了新的文献求助10
5秒前
yx阿聪发布了新的文献求助10
5秒前
5秒前
科研rookie发布了新的文献求助10
5秒前
丘比特的应助被taipingyang采纳,获得10
5秒前
科目三的应助被AZ采纳,获得10
6秒前
李李完成签到,获得积分10
6秒前
LL发布了新的文献求助10
6秒前
Gaoge发布了新的文献求助10
7秒前
7秒前
小梨子完成签到,获得积分10
7秒前
Fan完成签到,获得积分10
8秒前
大模型的应助被绘海采纳,获得10
8秒前
9秒前
ZC完成签到,获得积分10
9秒前
coco发布了新的文献求助10
10秒前
10秒前
10秒前
唐怡秀完成签到 ,获得积分10
10秒前
Jasper的应助被MiraITowA采纳,获得10
11秒前
tony发布了新的文献求助10
12秒前
充电宝的应助被科研rookie采纳,获得10
13秒前
joyce发布了新的文献求助10
13秒前
13秒前
13秒前
ll发布了新的文献求助10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Monte Cassino in the Middle Ages Volume I 310
JUSTIFICATION OF SMALL-SCALE MODELS: AN INDUSTRY PERSPECTIVE 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8156173
求助须知:如何正确求助?哪些是违规求助? 9552394
关于积分的说明 21709670
捐赠科研通 7745323
什么是DOI,文献DOI怎么找? 3426395
关于科研通互助平台的介绍 2551332
邀请新用户注册赠送积分活动 2470202